RAC 0.80% $1.86 race oncology ltd

Ann: Appendix 4E & Annual Report, page-12

  1. 498 Posts.
    lightbulb Created with Sketch. 613

    Amazing progress on Zantrene development made this FY
    Roadmap lined out for 2023 (and onward)
    Financials are excellent, very disciplined spending.
    $33.5M cash in the bank. Enough for 2-3 years of programs spending even at increased pace.
    Remuneration of Directors on the rise, but overall, remains in line with peers and given the amount of hard work done.
    Chairman's interests aligned with shareholders interest
    Communication to shareholders is, as always, top notch
    Steady shareholder structure, with the exception of a few that we already knew about (BG, MOF).Well absorbed

    Congrats to the whole RAC team, for this year's excellent achievements. I am very much looking forward to FY2023 which in John Cullity's own words will be transformative.
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
(20min delay)
Last
$1.86
Change
-0.015(0.80%)
Mkt cap ! $316.8M
Open High Low Value Volume
$1.88 $1.88 $1.79 $163.0K 89.00K

Buyers (Bids)

No. Vol. Price($)
2 34299 $1.84
 

Sellers (Offers)

Price($) Vol. No.
$1.86 3635 1
View Market Depth
Last trade - 16.10pm 18/07/2024 (20 minute delay) ?
RAC (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.